WuXi AppTec has filed a patent for a process involving trans-pseudotyping to produce recombinant adeno-associated virus (AAV) particles with different cell tropisms. The method includes expressing AAV cap genes in first and second host cells to generate AAV particles for efficient production and therapeutic applications. GlobalData’s report on WuXi AppTec gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights WuXi AppTec Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on WuXi AppTec, AI-assisted drug screening was a key innovation area identified from patents. WuXi AppTec's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Process for producing recombinant aav particles with different cell tropisms

Source: United States Patent and Trademark Office (USPTO). Credit: WuXi AppTec Co Ltd

A patent application (Publication Number: US20240026378A1) describes a process for producing recombinant adeno-associated virus (AAV) particles. The process involves culturing first host cells containing nucleic acid molecules encoding a recombinant AAV genome, AAV cap genes, AAV rep genes, and viral helper genes to produce first recombinant AAV particles. These particles are then used to infect second host cells, where additional AAV cap genes are expressed to produce second recombinant AAV particles. The second host cells are cultured to produce AAV particles encapsidated by specific capsid polypeptides, with the amino acid sequence identity between the first and second capsid polypeptides being less than 99.5% and at least 50%.

Furthermore, the process includes steps for introducing nucleic acid molecules into host cells, selecting specific host cell types such as HEK293, HEK293T, HEK293A, PerC6, or 911 cells, and targeting third host cells such as neurons, hepatocytes, muscle cells, stem cells, immune cells, and various other cell types. The patent application also covers the purification and isolation of the recombinant AAV particles, as well as the use of recombinant adenovirus with repressible Major Late Promoter (MLP) for gene regulation. Additionally, the application details the production of AAV particles of specific serotypes, such as AAV2 and AAV9, and their derivatives, along with the potential applications in targeting cancer cells and stem cells for therapeutic purposes.

To know more about GlobalData’s detailed insights on WuXi AppTec, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies